Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

REGAIN

Financiado

Cerrado

REgeneration of inner ear hair cells with GAmma secretase INhibitors to regain h...

REgeneration of inner ear hair cells with GAmma secretase INhibitors to regain hearing in patients with sensorineural hearing loss Hearing loss is a chronic non-communicable disease disabling over 328 million adults, and 32 million children worldwide. Sensorineural hearing loss due to loss of auditory hair cells was long thought to be irreversible. However, r... ver más

31/10/2019

AUDION

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

AUDION THERAPEUTICS BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-10-31

PHC-13-2014: New therapies for chronic non-commu...

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

AUDION

1.82M€ | Lider

TTOP

125.00K€ | Participante

UOA

287.47K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

AFHELO Preclinical proof of concept of AF243 potency to prevent and... 4M€ Cerrado

NeuEar Neurotrophic Cochlear Implant for Severe Hearing Loss 8M€ Cerrado

BFU2014-53203-P COMO SE FORMA EL OIDO INTERNO:GENES, NEURONAS Y FORMA 3D 151K€ Cerrado

iHEAR Gene therapy of inherited and acquired hearing loss 2M€ Cerrado

OTOSTEM Human stem cell applications for the treatment of hearing lo... 8M€ Cerrado

PID2020-117662GB-I00 DESDE DECODIFICANDO LAS IDENTIDADES DE LAS NEURONAS DEL OIDO... 218K€ Cerrado

Duración del proyecto: 54 meses Fecha Inicio: 2015-04-07
Fecha Fin: 2019-10-31

Líder del proyecto

AUDION THERAPEUTICS BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Hearing loss is a chronic non-communicable disease disabling over 328 million adults, and 32 million children worldwide. Sensorineural hearing loss due to loss of auditory hair cells was long thought to be irreversible. However, recent animal studies have demonstrated that pharmacological inhibition of cell signalling via Notch receptors using gamma-secretase inhibitors (GSIs) can regenerate hair cells and partially restore hearing capacity. This novel therapeutic concept provides the first promising lead for actual treatment of hearing loss. Clinical validation of these findings is the next crucial stepping stone in the development of a regenerative therapy for hearing loss. The ambition of REGAIN is to repurpose a GSI molecule for this indication by shifting from systemic to local treatment. The objective of the REGAIN project is to demonstrate and exploit the efficacy of locally administered GSIs to improve hearing through regeneration of inner ear hair cells with a lasting effect. The project will involve 1) the upscaling of GMP production of the clinical GSI candidate, 2) the generation of preclinical data on GSI dosing and local safety, 3) medical ethical clinical trial approval and 4) the demonstration of proof of concept for GSI for treatment of patients with recent onset sensorineural hearing loss. Small molecule drugs targeting the underlying biological causes of hearing loss in a safe way are expected to meet a real medical need for millions of patients, who currently rely on the limited benefits provided by hearing aids or cochlear implants. The partners involved in REGAIN represent the current state of the art in regenerative hearing loss research in the EU. REGAIN will break through that current state of the art, and will advance the first highly promising pharmaceutical treatment of hearing loss through clinical testing.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores